Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT04606550

MonaLisa Laser Intervention for Post-Menopausal Breast Cancer Patients: A SHE CAN Study

Randomized Clinical Trial Comparing the MonaLisa Laser Versus Vaginal Estrogen in Post-Menopausal Breast Cancer Patients: a SHE CAN Non-inferiority Study

Status
Withdrawn
Phase
N/A
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Mount Sinai Hospital, Canada · Academic / Other
Sex
Female
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to assess the efficacy of a fractional CO2 laser ("SmartXide2 - V2LR", DEKA M.E.L.A., Florence - Italy) "the Laser" in the treatment of genitourinary symptoms of menopause, female sexual function, and urogenital health in comparison to vaginal estrogen. Only breast cancer patients who have HR (-) breast cancer are planning to be included in the vaginal estrogen group.

Detailed description

The investigators aim to determine the efficacy of the MonaLisaTouch Laser in comparison with vaginal estrogen in the management and treatment of GSM symptoms resulting in vaginal atrophy, sexual dysfunction and a decreased quality of life in women with a history of breast cancer. Patients will be stratified according to menopausal status prior to breast cancer therapy and HR tumor status. Fractional CO2 laser therapy has been approved by Health Canada for use in menopausal women with GSM, nevertheless long term efficacy and safety data is lacking in the breast cancer survivor population. In the short term (i.e. 6 month follow up), research has shown that this therapy is a safe and effective treatment that has promising benefits with little to no reported adverse events.

Conditions

Interventions

TypeNameDescription
DEVICEMicroablative Fractional CO2 Laser TherapyMicroablative Fractional CO2 Vaginal Laser Therapy

Timeline

Start date
2021-09-01
Primary completion
2021-12-01
Completion
2022-07-01
First posted
2020-10-28
Last updated
2022-10-13

Source: ClinicalTrials.gov record NCT04606550. Inclusion in this directory is not an endorsement.